Ultrarapid Metabolizer: What It Means and Why It Matters

An ultrarapid metabolizer (UM) is someone with significantly increased enzyme activity in a drug-metabolizing gene — most commonly the CYP2D6 gene. This is usually caused by carrying extra copies of a functional gene (gene duplication or multiplication). If you have received this result, it means your body processes certain medications much faster than expected, which can have serious clinical consequences.

What Causes Ultrarapid Metabolizer Status?

Ultrarapid metabolism occurs through two main mechanisms:

• CYP2D6 gene duplication: Instead of the standard two copies of the CYP2D6 gene, some people carry three or more functional copies. Each additional copy increases enzyme production. A CYP2D6 activity score greater than 2.0 indicates ultrarapid metabolizer status.
• CYP2C19 increased-function alleles: The CYP2C19*17 allele increases gene expression. Carrying one or two copies of *17 (e.g., *1/*17 or *17/*17) results in rapid or ultrarapid metabolizer status for the CYP2C19 gene.

Why Ultrarapid Metabolism Matters

Ultrarapid metabolizer status has different — and sometimes opposite — consequences depending on the type of medication:

Active Drugs (Work As-Is)

The drug is broken down too quickly, potentially dropping below therapeutic levels before the next dose. This can make the medication ineffective at standard doses.

• Amitriptyline — CYP2D6 UMs clear the drug rapidly. CPIC recommends avoiding amitriptyline or considering an alternative not primarily metabolized by CYP2D6.
• Venlafaxine — Ultrarapid CYP2D6 metabolism increases conversion to the active metabolite desvenlafaxine, which may alter the drug's therapeutic profile.

Prodrugs (Must Be Activated)

The drug is converted to its active form too rapidly, which can produce dangerously high levels of the active metabolite. This is the more serious scenario.

• Codeine — CYP2D6 UMs convert codeine to morphine much faster than normal, which can cause respiratory depression — a potentially life-threatening adverse effect. The FDA restricted codeine use in children after tonsillectomy/adenoidectomy in 2013, and a boxed warning citing CYP2D6 ultrarapid metabolism now appears on the codeine label following a 2017 update that expanded pediatric restrictions and added a breastfeeding warning. CPIC extends this concern to ultrarapid metabolizers of any age, classifying codeine in CYP2D6 ultrarapid metabolizers as "avoid use" (Level A evidence).
• Tramadol — Similar mechanism to codeine. CYP2D6 ultrarapid metabolism increases O-desmethyltramadol production, raising the risk of opioid toxicity.

Clinical Recommendations for Ultrarapid Metabolizers

CPIC guidelines provide specific, drug-level recommendations for ultrarapid metabolizers. The actions range from dose adjustments to complete avoidance:

These are selected examples. See individual medication pages for complete CPIC guideline text and evidence levels.

How Common Is Ultrarapid Metabolizer?

Ultrarapid metabolizer prevalence varies significantly by ancestry:

• CYP2D6 UM: A CPIC-compiled analysis of major world populations found genotypic ultrarapid metabolizer prevalence ranging from about 1% to 21% overall, with the highest rates concentrated in North African, Middle Eastern, and some East African populations, driven by a higher frequency of CYP2D6 gene duplications.
• CYP2C19 UM/RM: Approximately 5–30% depending on ancestry, driven by the *17 increased-function allele. Higher prevalence in European and some African populations.

Ultrarapid Metabolizer vs. Other Phenotypes

• Poor metabolizer — The opposite end: very low or absent activity. Drugs accumulate instead of being cleared too fast.
• Intermediate metabolizer — Reduced but not absent activity. Less extreme than PM.
• Normal metabolizer — Expected enzyme function. Standard dosing applies.
• Rapid metabolizer — Modestly increased activity (CYP2C19 *1/*17). Less extreme than UM but still clinically relevant for some drugs.

Important Note on Consumer DNA Data

CYP2D6 ultrarapid metabolizer status is primarily caused by gene duplications — carrying three or more copies of the CYP2D6 gene. Consumer genotyping arrays from 23andMe and AncestryDNA cannot reliably detect gene copy number. This means a CYP2D6 ultrarapid metabolizer would be invisible to a consumer-data analysis. Because that misses the exact result that matters most, DecodeMyBio does not call CYP2D6 from raw data at all — rather than guess, we tell you the truth: CYP2D6 needs a specialized caller that a consumer array does not provide, and we will never invent a result it cannot support.

CYP2C19 ultrarapid/rapid metabolizer status, which is driven by the *17 allele (an SNP, not a structural variant), is detectable from consumer DNA data.

If you have clinical reasons to suspect ultrarapid CYP2D6 metabolism — for example, codeine or tramadol providing no pain relief, or antidepressants wearing off before the next dose — discuss provider-ordered pharmacogenomic testing with your healthcare provider. For more on consumer data limitations, see our limitations page.